Clinical Trials | September 11, 2024
Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS patients experience neuroinflammation and rapid neurodegeneration
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
The recent inspection covered both cGMP and PAI processes
The patient has been isolated in a designated hospital and is currently stable
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
Subscribe To Our Newsletter & Stay Updated
